【大河财立方 记者 夏晨翔】近日，一则"西北大学新任副校长范代娣，持股市值达443亿元，晋升新一 任陕西首富"的消息引起广泛关注。 范代娣与丈夫严建亚共同打造的商业版图逐渐浮出水面，叠加其学术身份，瞬间成为舆论焦点。 西北大学官网显示的范代娣简历 西北大学官网显示，2025年4月，范代娣出任西北大学党委委员、常委、副校长。 在商业领域，范代娣与丈夫严建亚二人通过掌控巨子生物（02367.HK）和三角防务（300775.SZ）两家 上市公司，以及在产业链上下游的深入布局，已构建起横跨生物科技与国防军工的资本矩阵。 2000年，范代娣与严建亚在西安高新区共同创立了巨子生物。2022年11月，巨子生物在港交所主板上 市，成为"胶原蛋白第一股"。 在招股书中，范代娣为巨子生物联合创始人、执行董事兼首席科学官；其丈夫严建亚担任法定代表人、 董事长及总经理；女儿严钰博则担任巨子生物的董秘一职。 值得一提的是，2007年，西北大学与巨子生物共同组建陕西省生物材料与发酵工程技术研究中心，主要 研发方向为生物产品的发酵中试放大技术、生物医用材料的研究与开发、组织工程的研究与开发等。 组建时，身为西北大学化工学院副院长的范代娣兼 ...

Core Insights - The article highlights the rise of Fan Daidi and her husband Yan Jianya as the new richest individuals in Shaanxi, with a combined stock value exceeding 45 billion RMB, primarily due to their holdings in Juzhibio and Triangle Defense [1][5]. Company Performance - Juzhibio's market capitalization reached 83.6 billion HKD (approximately 77.3 billion RMB) as of May 12, 2024, while Triangle Defense's market cap was 14.7 billion RMB [1]. - Juzhibio reported a revenue of 5.54 billion RMB in 2024, marking a year-on-year growth of 57.2%, and a net profit of 2.06 billion RMB, up 42.1% from the previous year [7][8]. - Triangle Defense's revenue for the same period was 1.59 billion RMB, with a significant decline of 30.02%, and a net profit of 380 million RMB, down 49.12% [7][9]. Shareholding Structure - Fan Daidi and Yan Jianya hold a combined 57.32% stake in Juzhibio, with Yan Jianya's effective shareholding being 13.77% after considering various entities [1][2]. - The couple's total shareholding value reached 46.3 billion RMB, surpassing other notable wealthy individuals in the region [5]. Historical Context and Growth - Juzhibio has shown remarkable growth since its inception in 2001, becoming the largest collagen-based skincare company in China by 2019 [6]. - The company has experienced substantial revenue growth rates from 2020 to 2024, with annual growth rates of 24.44%, 30.41%, 52.30%, 49.05%, and 57.17% respectively [6]. Research and Development Contributions - Fan Daidi's contributions to the field of biomanufacturing, particularly in the synthesis of complex pharmaceutical molecules, have been pivotal to Juzhibio's success [6].

极目新闻记者 陈洋洋 据新财富杂志日前报道，西北大学副校长范代娣以440亿元的身家成为陕西省首富。5月13日，极目新闻记者就此事致电西北大学宣传处，工作人员表示，目 前没有关注到该消息，范代娣具体的个人信息可以通过官网了解。 13日上午，记者联系巨子生物基因技术股份有限公司，该公司一客服工作人员表示，并不清楚范代娣成为陕西省首富一事。 范代娣和学生们（图源：西北大学官网） 范代娣个人简历（图源：西北大学官网） 随后，记者登录学校官网查询，公开信息显示，范代娣，女，汉族，1966年1月生，陕西蒲城人，中共党员，研究生学历，工学博士，教授，博士生导师。 现任西北大学党委常委、副校长，化工学院院长。分管国际合作部（国际教育学院）、经营性资产管理有限公司。联系外国语学院、化学与材料科学学院。 1994年，于华东理工大学生物工程系博士毕业后进入西北大学工作。历任西北大学化工学院副院长、院长。2025年4月，任西北大学党委委员、常委、副校 长。 范代娣（资料图） 范代娣与丈夫创办巨子生物 据了解，范代娣与丈夫严建亚于2000年9月创立了巨子生物基因技术股份有限公司。自2019年起，巨子生物成为中国最大的胶原蛋白专业皮肤护 ...

Core Insights - The performance of domestic beauty companies in China is showing significant divergence, with some achieving remarkable growth while others face declines, indicating a reshaping of the market landscape [1][4][42] Group 1: Company Performance - Proya has become the first domestic beauty company to enter the 10 billion yuan club, with a revenue of 10.778 billion yuan, growing by 21.04% [2] - Other companies like Shangmei and Juzi Biological also reported substantial revenue increases of 62.08% and 57.17% respectively, while Shanghai Jahwa experienced a revenue decline of 13.93% [2][3] - Six beauty companies have revenues exceeding 5 billion yuan, suggesting that this threshold will soon become a significant benchmark for the top 10 domestic beauty brands [1] Group 2: Profitability Trends - Juzi Biological leads in profitability with a profit of 2.062 billion yuan, up 42.06%, while Proya's profit reached 1.552 billion yuan, growing by 30% [3] - In contrast, Shanghai Jahwa reported a loss of 833 million yuan, marking a 266.60% decline, highlighting the stark differences in profitability among companies [3][11] Group 3: Market Dynamics - The current market dynamics indicate a shift towards efficacy-driven products, with companies that successfully launched standout products seeing better performance [4][5] - The competition is intensifying, with new entrants emerging and established brands needing to adapt to changing consumer preferences and market trends [7][30] Group 4: R&D and Strategic Focus - Companies are increasingly focusing on R&D, with most reporting a rise in R&D expenditures, indicating a strategic shift towards innovation and efficacy [20][21] - The trend of acquisitions and investments in technology is becoming a key strategy for companies aiming to enhance market share and scale [23][24] Group 5: Emerging Opportunities - The male skincare market is growing rapidly, presenting new opportunities for brands to capture this segment [36] - The aging population is creating demand for products targeting older consumers, which remains largely untapped [39] - As online sales plateau, brands are shifting focus to offline channels, indicating a potential new battleground for market share [40]

西北大学官网资料显示，范代娣出生于1966年1月，今年59岁，陕西蒲城人，从华东理工大学生物工程 系博士毕业后，便进入西北大学工作，历任西北大学化工学院副院长、院长。今年4月，范代娣出任西 北大学党委委员、常委、副校长。 2000年，范代娣用基因工程技术高密度发酵生产的一种类人胶原蛋白宣告问世。2001年，范代娣申请了 中国第一个重组胶原蛋白发明专利——"一种类人胶原蛋白及其生产方法"。同年9月，范代娣夫妻二人 创立了巨子生物基因技术股份有限公司。 自2019年起，巨子生物成为中国最大的胶原蛋白专业皮肤护理产品公司，也是全球范围内拥有最大重组 胶原蛋白产能的企业之一。2022年11月，该公司在港股上市。 年报显示，去年，巨子生物实现营收55.39亿元，同比增长57.2%；实现归属净利润20.62亿元，同比增 长42.1%，公司毛利率达到82.09%。 今年4月上任的西北大学女副校长范代娣及其丈夫以持股市值超450亿元的身价，成为新一任陕西首富。 目前，范代娣及其丈夫严建亚名下有巨子生物(02367.HK)和三角防务(300775)两家上市公司。截至5月 12日收盘，巨子生物的市值为836亿港元(约合人民币77 ...

Summary of Key Points from Conference Call Records Industry Overview - The beauty industry is currently experiencing a transformation, with a focus on technological beauty, refined operations, and AI assistance as highlighted during the recent 聚美丽大会 (Beauty Conference) held in Shanghai [1][3] - The conference emphasized the need for innovation in raw materials and operational excellence to enhance competitiveness in the market [4] Company Insights Shanghai Jahwa (上海家化) - For the year 2024, Shanghai Jahwa reported a revenue of 5.679 billion yuan, a year-on-year decline of 13.93%, and a net loss of 833 million yuan, a significant drop of 266.60% [2] - In Q1 2025, the company recorded a revenue of 1.704 billion yuan, down 10.59%, with a net profit of 217 million yuan, a decrease of 15.25% [2] - The personal care segment generated 2.379 billion yuan, down 3.42%, while the beauty segment saw a revenue of 1.050 billion yuan, down 29.81% [2] - A 2025 employee stock ownership plan aims to incentivize 45 mid-to-senior level employees, with targets set for profitability recovery and growth in the following years [2] Estée Lauder (雅诗兰黛) - Estée Lauder reported net sales of 3.55 billion USD (approximately 25.808 billion yuan) for Q3 of fiscal year 2025, reflecting a 10% decline, while net profit decreased by 53% [5] - Despite the overall decline, the gross margin has improved for four consecutive quarters, increasing by over 300 basis points, indicating effective recovery and growth strategies [5] - The skincare and haircare segments saw significant declines, while the fragrance segment experienced a 10% increase in revenue [5] - In the Asia-Pacific region, net sales fell by 1%, but China saw single-digit growth, helping to offset some market declines [5] Competitive Landscape - Domestic brands are aggressively competing in the beauty market, leading to a rebound in international brands, which is expected to drive demand growth [2] - The conference highlighted the importance of leveraging AI and refined operations to maintain competitiveness in a challenging market environment [4] Additional Insights - The 聚美丽大会 served as a platform for industry leaders to discuss trends and challenges, including the potential of emerging markets and the impact of tariffs [4] - Recommendations for investment include companies with strong brand matrices and innovative products, such as 上美股份, 珀莱雅, and 丸美生物, as well as e-commerce platforms like 若羽臣 [5]

Core Insights - The domestic beauty industry in China is expected to undergo a significant restructuring by 2025, with companies showing rapid growth driven by strong single-brand performance and a shift in consumer focus towards verified efficacy rather than just ingredient composition [2][10] Revenue Performance - Proya has become the first domestic beauty company to surpass 10 billion yuan in revenue for 2024, achieving 10.779 billion yuan, maintaining its top position [4] - Shangmei Co. has shown the fastest revenue growth, with a 62.1% increase from 4.191 billion yuan in 2023 to 6.793 billion yuan in 2024, rising from sixth to second place among the sample companies [3][4] - Other notable companies include Betaini with 5.736 billion yuan, Shanghai Jahwa with 5.679 billion yuan, and Juzhibio with 5.54 billion yuan, all showing varying degrees of growth [4] Brand Performance - Shangmei's brand Han Shu generated nearly 5.6 billion yuan in 2024, accounting for 82.3% of the group's total revenue, with a growth rate of 73.7% [5] - Juzhibio's brand Kefu Mei achieved 4.54 billion yuan in revenue, representing 82% of its total revenue, with a growth rate of 62.9% [6] Market Trends - The popularity of hyaluronic acid is declining, while "recombinant collagen" is emerging as a lucrative ingredient, reflecting a shift in consumer preferences towards efficacy-driven skincare [7][9] - The market is witnessing a transition from ingredient-focused to efficacy-focused products, with companies like Proya leveraging this trend to capture market share [10][11] R&D and Investment - There is a growing disparity between revenue growth and R&D investment among companies, with Proya's R&D expenditure at only 1.95% of total revenue, the lowest among the sample companies [12] - In contrast, Juzhibio, despite its rapid revenue growth, has a low R&D investment ratio of 1.9%, indicating a potential risk in long-term sustainability [12] Industry Dynamics - The beauty industry is moving towards a phase where product efficacy and R&D capabilities are becoming critical competitive factors, as opposed to relying solely on marketing [13] - The gap in revenue between leading and mid-tier companies is widening, suggesting a trend towards market consolidation and structural transformation within the industry [13]

Core Viewpoint - The article discusses the rise of Fan Daidi and her husband Yan Jianya as the new richest couple in Shaanxi, primarily due to their holdings in Juzi Biological and Triangle Defense, with a combined market value of nearly 900 billion yuan [2][9]. Group 1: Personal Background and Wealth - Fan Daidi holds a stock value of 443 billion yuan and has recently become the richest person in Shaanxi [2][5]. - The couple's daughter, Yan Yubo, has been rigorously trained and holds multiple financial certifications, currently serving as the secretary and executive director of Juzi Biological, with a salary increase from 140,000 yuan in 2023 to 360,000 yuan in 2024 [3][16]. Group 2: Company Overview - Juzi Biological - Juzi Biological, a leader in the field of recombinant collagen, has seen its revenue grow from 9 billion yuan in 2019 to 55 billion yuan in 2024, marking a fivefold increase over five years [18]. - The company has a projected revenue of 45.4 billion yuan in 2024, with a year-on-year growth of 62.9%, and a gross margin of 82% [17][21]. - Juzi Biological has raised a total of 45.6 billion yuan through various financing rounds since its IPO in 2022, while distributing 2.3 billion yuan in dividends to the Fan family [25] [24]. Group 3: Company Overview - Triangle Defense - Triangle Defense, which specializes in aerospace and military components, has a market value exceeding 100 billion yuan, with Yan Jianya controlling 16.09% of the shares [26][27]. - The company has experienced significant revenue growth from 4.7 billion yuan in 2018 to 24.9 billion yuan in 2023, but has faced a decline in 2024 due to reduced orders from major clients [28]. - Triangle Defense is currently under regulatory scrutiny for various management issues, which could impact its future performance [28].

Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]

Summary of the Conference Call Records Industry Overview - The beauty and personal care industry is experiencing an increase in penetration rates and rising prices, showing stronger growth compared to traditional food and beverage sectors, leading new consumption trends [1][7] - Domestic brands are rapidly rising in the beauty and personal care market, replacing foreign brands, particularly Japanese and Korean brands, which are showing significant declines [1][3] Key Financial Performance - **Personal Care Segment**: - 2024 revenue growth of 19% and net profit growth of 25% - Q1 2025 revenue growth of 29% and profit growth of 13%, driven by product innovation and Douyin channel [1][6] - **Medical Aesthetics Segment**: - 2024 revenue growth of 16% and net profit growth of 22% - Q1 2025 revenue and profit remained flat, with significant internal differentiation [1][9] - **Cosmetics Industry**: - 2024 revenue growth of 11% and net profit decline of 9% (11% growth after excluding anomalies) - Some companies like Juzhi Biotechnology and Mao Ge Ping performed exceptionally well [1][10] Channel Performance - Douyin channel is noted for its dual role in marketing and sales, with high initial costs but potential for improved profitability as brand influence expands to other channels [4][8] - In April 2025, beauty brands on Douyin showed strong performance, with several brands achieving over 100% growth [11] Company-Specific Insights - **Ruo Yuchen**: - Q1 2025 revenue and profit growth exceeded 200% for its free brand and over 150% for its household cleaning brand [12] - **Deng Kang Oral Care**: - Q1 2025 revenue and profit growth of 15%-20%, with online channels showing over 200% growth [14] - **Polaire**: - Q1 2025 saw unexpected profit growth due to improved gross margins and optimized sales expenses [16] - **Mao Ge Ping**: - April 2025 Douyin channel growth of over 30% [17] - **Perfect Bio**: - Q1 2025 revenue growth of 28% and net profit close to 30% [18] - **Runben**: - Q1 2025 revenue growth of 44%, with a focus on new product launches [19] Market Trends and Investment Recommendations - The beauty and personal care sector is expected to continue leading new consumption trends, with investment strategies focusing on companies with strong innovation capabilities and those showing positive changes [1][7][26] - Recommended stocks include Ruo Yuchen, Deng Kang Oral Care, and Runben in the personal care segment, and high-end domestic brands like Mao Ge Ping and companies in the collagen segment like Juzhi Biotechnology [26] Additional Insights - The beauty and personal care sector is more sensitive to product demand, innovation, and channel changes compared to other consumer goods, providing a natural premium and innovation potential [24] - The overall market for personal care, beauty, and medical aesthetics is expected to show strong growth, driven by product innovation and structural opportunities [25]